Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below Two Hundred Day Moving Average of $8.50

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRXGet Free Report) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $8.50 and traded as low as $4.96. Eagle Pharmaceuticals shares last traded at $5.24, with a volume of 80,452 shares trading hands.

Eagle Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.67 and a current ratio of 2.16. The company has a 50 day moving average price of $5.66 and a 200 day moving average price of $8.50. The company has a market capitalization of $68.07 million, a price-to-earnings ratio of 4.44 and a beta of 0.42.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Point72 Hong Kong Ltd acquired a new position in Eagle Pharmaceuticals during the 2nd quarter valued at about $34,000. Point72 Middle East FZE acquired a new position in Eagle Pharmaceuticals during the 4th quarter valued at about $53,000. Headlands Technologies LLC boosted its stake in Eagle Pharmaceuticals by 263.4% during the 3rd quarter. Headlands Technologies LLC now owns 2,326 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,686 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in Eagle Pharmaceuticals during the 3rd quarter valued at about $79,000. Finally, Royal Bank of Canada boosted its stake in Eagle Pharmaceuticals by 1,590.9% during the 3rd quarter. Royal Bank of Canada now owns 3,348 shares of the specialty pharmaceutical company’s stock valued at $88,000 after purchasing an additional 3,150 shares during the last quarter. Institutional investors and hedge funds own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

(Get Free Report)

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Featured Articles

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.